Guo Fengli, Fu Honghai, Wang Yuhua, Hua Yitong, Wang Xiaohong, Zhang Yingzhe, Jian Jinbo, Jia Zhongming, Zhang Guoqiang
Department of Thyroid and Breast Surgery, Binzhou Medical University Hospital, Binzhou, China.
Department of Oral and Maxillofacial Surgery, Binzhou Medical University Hospital, Binzhou, China.
Front Oncol. 2024 Sep 2;14:1442713. doi: 10.3389/fonc.2024.1442713. eCollection 2024.
Parotid gland metastases originating from breast origin are extremely rare, with their clinical presentation, therapeutic approaches, and prognostic indicators remaining to be elucidate.
A comprehensive retrospective review was conducted, analyzing the clinical characteristics and prognostic factors of 57 patients diagnosed with parotid metastasis of breast cancer in the existing literature. Notably, our study included two unique cases of patients who developed contralateral and ipsilateral parotid metastases, occurring 5 years and 32 years respectively after primary surgery. This analysis aimed to provide a deeper understanding of the disease presentation and identify potential prognostic indicators.
The primary clinical manifestation presented in breast cancer patients with parotid metastases was painless masses in the parotid glands, synchronously or metachronously occurred with primary breast tumors. The predominant pathological subtype among these patients was invasive ductal carcinoma. Out of the 57 patients studied, 24 (42.1%) exhibited metastases solely in the ipsilateral parotid gland, while 18 cases (31.6%) involved either the contralateral or bilateral parotid gland. Patients may solely exhibit metastasis in the parotid gland, or they may present with concurrent multiple metastases in other organs. Patients who suffered from parotid metastases, either merely or accompanied with bone-only metastasis, exhibited significantly longer overall survival (OS) rates compared to those who had concomitant metastases in other organs (1.23 ± 0.26 years vs 4.46 ± 0.77 years, P=0.046). While no statistically significant differences in OS were observed among patients presenting with metastases in the ipsilateral, contralateral, or bilateral parotid glands, a notable variance could be discerned from the Kaplan-Meier curve analysis. Additionally, no significant difference in survival was exhibited between patients with different interval of progression from primary breast sites to initial diagnosis of parotid metastases (uDF), nor for patients who were treated with surgery or palliative therapy.
Parotid metastasis, a rare and distinctive form of breast cancer metastasis, demands particular scrutiny in patients exhibiting metastasis to multiple organs or contralateral or bilateral parotid glands.
源自乳腺的腮腺转移瘤极为罕见,其临床表现、治疗方法及预后指标仍有待阐明。
进行了一项全面的回顾性研究,分析现有文献中57例诊断为乳腺癌腮腺转移患者的临床特征及预后因素。值得注意的是,我们的研究纳入了两例独特的病例,分别在初次手术后5年和32年出现对侧和同侧腮腺转移。该分析旨在更深入了解疾病表现并确定潜在的预后指标。
乳腺癌腮腺转移患者的主要临床表现为腮腺无痛性肿块,与原发性乳腺肿瘤同时或异时出现。这些患者中占主导地位的病理亚型是浸润性导管癌。在所研究的57例患者中,24例(42.1%)仅在同侧腮腺出现转移,而18例(31.6%)累及对侧或双侧腮腺。患者可能仅在腮腺出现转移,也可能同时在其他器官出现多发转移。与那些在其他器官有合并转移的患者相比,仅发生腮腺转移或伴有单纯骨转移的患者总生存期(OS)显著更长(1.23±0.26年对4.46±0.77年,P=0.046)。虽然同侧、对侧或双侧腮腺出现转移的患者之间OS无统计学显著差异,但从Kaplan-Meier曲线分析中可看出明显差异。此外,从原发性乳腺部位到腮腺转移初始诊断的不同进展间隔(uDF)的患者之间,以及接受手术或姑息治疗的患者之间,生存期均无显著差异。
腮腺转移是乳腺癌转移的一种罕见且独特的形式,对于出现多器官转移或对侧或双侧腮腺转移的患者需要特别关注。